Odyssey Thera Granted U.S. Patent for Anim... (y Thera visit http://www.odysseythera.c...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Odyssey Thera Granted U.S. Patent for Animal Imaging

Date:12/12/2007

y Thera visit http://www.odysseythera.com.

SOURCE Odyssey Thera, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination

Post Your Comments:

Breaking Biology Technology:EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6 Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2

[0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO [0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)[0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)

Other Biology Technology:BNBI Employees Donate 1,000 Backpacks to Frederick County School Children 2 Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2 Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3 Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4 Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5 Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6 Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors 2 Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors 3

BNBI Employees Donate 1,000 Backpacks to Frederick County School Children Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors

Breaking Biology News(10 mins):Type 2 diabetes gene predisposes children to obesity 2 Delivering medicine directly into a tumor 2 Researchers use computational models to study fear 58567 1 Researchers use computational models to study fear 58567 2 Securing biological select agents and toxins will require developing a culture of trust 10190 1 Securing biological select agents and toxins will require developing a culture of trust 10190 2 Securing biological select agents and toxins will require developing a culture of trust 10190 3 Lack of Social Interaction Affects Health Outcomes of Breast Cancer Stress from loneliness leads to increased tumor growth Decrease breast cancer r 58565 1 Lack of Social Interaction Affects Health Outcomes of Breast Cancer Stress from loneliness leads to increased tumor growth Decrease breast cancer r 58565 2 Lack of Social Interaction Affects Health Outcomes of Breast Cancer Stress from loneliness leads to increased tumor growth Decrease breast cancer r 58565 3 Lack of Social Interaction Affects Health Outcomes of Breast Cancer Stress from loneliness leads to increased tumor growth Decrease breast cancer r 58565 4

[0] U of A's David Schindler confirms untold levels of oil sands pollution on the Athabasca [0] Type 2 diabetes gene predisposes children to obesity [0] Delivering medicine directly into a tumor

Other Biology News:UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine 2 UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine 3 UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine 4 Landfill cover soil methane oxidation underestimated 2 Experts lay to rest long-held misconceptions about high fructose corn syrup at ILSI-USDA workshop 2 Experts lay to rest long-held misconceptions about high fructose corn syrup at ILSI-USDA workshop 3

UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine Landfill cover soil methane oxidation underestimated Experts lay to rest long-held misconceptions about high fructose corn syrup at ILSI-USDA workshop

Biology Products:

Mouse Anti-Hamartin Monoclonal Antibody, Unconjugated, Clone 1B2 from Cell Signaling Technology Mouse Anti-Mouse Ly 6C.2(Ly 28.2) Monoclonal Antibody, Unconjugated, Clone 5075-3.6 from CEDARLANE Laboratories Limited Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology